Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate.
Minerva Urol Nefrol
; 69(3): 271-277, 2017 Jun.
Article
in En
| MEDLINE
| ID: mdl-27813398
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Osteoporosis
/
Alendronate
/
Bone Density Conservation Agents
/
Prostatic Neoplasms, Castration-Resistant
/
Denosumab
/
Hypogonadism
Type of study:
Clinical_trials
/
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Aspects:
Patient_preference
Limits:
Aged
/
Aged80
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Minerva Urol Nefrol
Journal subject:
NEFROLOGIA
/
UROLOGIA
Year:
2017
Document type:
Article
Affiliation country:
Italy
Country of publication:
Italy